#USA #New York #Class Action #Pomerantz LLP #ImmunityBio

ImmunityBio Class Action Lawsuit Announcement

Pomerantz LLP, a well-respected firm in securities and antitrust litigation, is taking action against ImmunityBio, Inc. This class action lawsuit arises from claims that ImmunityBio and certain officers may have participated in fraudulent practices regarding their securities.

Background of the Lawsuit

The class action concerns allegations of securities fraud and misconduct that may have affected investors who acquired ImmunityBio's shares during a specified period. Pomerantz LLP has made it clear that any investor who has experienced financial losses should reach out for assistance. The law firm has provided specific instructions for those wishing to be part of the collective effort to recover losses, emphasizing the urgent timeline for participation—May 26, 2026, being the pivotal date for appointing a Lead Plaintiff.

According to court documents, the crucial piece of information that has sparked the lawsuit includes a harsh notice from the U.S. Food and Drug Administration (FDA) received by ImmunityBio. The FDA's warning raised concerns about the misleading promotional claims related to Anktiva, a drug developed by ImmunityBio for treating bladder cancer. Despite previous warnings from the FDA, the company allegedly continued to promote the drug in a manner deemed deceptive, which included its appearances in national advertisements and media outlets, including podcasts.

Stock Market Reaction

This controversy resulted in a significant decline in ImmunityBio's stock value, dropping over 21% to close at $7.41 per share after the news broke on March 24, 2026. Investors who felt misled by these promotional strategies experienced immediate financial repercussions, leading to this class action complaint.

About Pomerantz LLP

Pomerantz LLP has a long-standing reputation for advocating for the rights of investors. Founded over 85 years ago, it has fought numerous battles against corporate misconduct and fraud. The firm is recognized for its successful track record of securing substantial recoveries for clients involved in class action lawsuits. Even now, Pomerantz continues to honor its founder’s legacy by striving to assist victims of financial fraud.

In the current lawsuit against ImmunityBio, the firm aims to bring justice for those affected by alleged securities violations. Investors are encouraged to contact Danielle Peyton from Pomerantz LLP if they want to participate in the class action. The firm ensures thorough communication and support throughout the process.

Conclusion

For anyone who has invested in ImmunityBio and is concerned about the implications of this lawsuit, this is a critical moment to act. Whether meant to provide solace to those experiencing losses or a rallying call for collective action, the Pomerantz Law Firm is staunchly advocating for investors.

Investors are reminded to take advantage of the opportunity to reclaim potential losses and stand together against corporate fraud. For further inquiries or to express interest in joining the lawsuit, reach out to Pomerantz LLP via the provided contact details.